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and if there is no response in the acute 
setting, cocaine is considered as the 
alternative.1
Topical apraclonidine is currently 
used for reduction of intra-ocular 
pressure in acute angle closure 
glaucoma and following YAG laser 
therapy. Because of the weak α1-
activity it has been shown to be useful 
in diagnosing Horner’s syndrome 
regardless of the site of the lesion. 
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Fig. 1. Before (above) and 30 minutes after 
apraclonidine.
The Medicines Control Council (MCC) alerts health care profes-
sionals to new prescribing information for promethazine.
The package inserts for promethazine-containing products 
are currently being updated to reflect a contraindication to use 
in children under the age of 2 years because of the potential for 
fatal respiratory depression in this age group.
Serious life-threatening cases of respiratory depression, 
including fatalities, have been reported with promethazine 
use in paediatric patients under 2 years of age.1-3 Promethazine 
should therefore not be administered to children under 2 years 
of age, and with caution to children of 2 years and older, and 
the lowest effective dose should be used in this group.2
Promethazine is used as an antihistamine, sedative, or 
anti-emetic.  There are several over-the-counter products 
that contain promethazine. These include antihistamines, 
combination analgesics/antipyretic paediatric syrups, 
and cough and cold preparations. Prescribers and users of 
these products should check the ingredients and review the 
revised package insert and patient information leaflet before 
prescribing or using promethazine-containing products.
Health care professionals are encouraged to report any 
adverse reactions associated with the use of medicines to 
the MCC’s National Adverse Drug Event Monitoring Centre 
(NADEMC) by telephone (021 447-1618) or fax (021 448-6181).
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Roche, in agreement and co-operation with health authorities 
(EMEA and Swissmedic), is recalling all batches of Viracept 
powder and tablets in Europe and some other regions of the 
world. The USA, Canada and Japan are not affected by this 
recall.
Roche has received several reports that some batches of 
Viracept 250 mg tablets have a strange odour. A detailed 
chemical analysis of the affected tablets showed they contain 
higher than normal levels of methane sulfonic acid ethyl ester. 
In the interests of patient safety Roche has decided to recall all 
batches of Viracept tablets and powder currently on the market. 
In South Africa, Roche is working closely with the Medicines 
Control Council in the process of recalling the products. 
Roche has also proactively frozen all stock of the powder and 
tablets at distributor and wholesaler levels, and is in the process 
of extending this to pharmacy level.
In South Africa it is estimated that less than 200 patients 
received Virecept therapy in the last year.  Patients are 
requested to contact their doctors to discuss alternative 
therapies.
For further information contact Vuyo Piti, Roche Communications 
Manager, tel. 011 928-8860, email: vuyo.piti@roche.com 
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